Michael Fisch MD MPH
@fischmd.bsky.social
Medical oncologist and palliative care physician. Avid sports fan, experienced in baseball analogy use. Senior medical director for Carelon and clinical professor (part-time) in general oncology at MD Anderson Cancer Center
Reposted by Michael Fisch MD MPH
Presented at #ASCO25:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
nej.md
May 30, 2025 at 9:05 AM
Presented at #ASCO25:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
Reposted by Michael Fisch MD MPH
Adding to growing evidence of #AI -based CT scan muscle analysis in cancer. Pts with mCRC receiving 1L FOLFOX or FOLFIRI with low skeletal muscle index had higher rates of ≥G3 neutropenia. journals.sagepub.com/eprint/RSAKM... #CancerCachexia @ryannipp.bsky.social @pallonccop.bsky.social
May 6, 2025 at 1:18 PM
Adding to growing evidence of #AI -based CT scan muscle analysis in cancer. Pts with mCRC receiving 1L FOLFOX or FOLFIRI with low skeletal muscle index had higher rates of ≥G3 neutropenia. journals.sagepub.com/eprint/RSAKM... #CancerCachexia @ryannipp.bsky.social @pallonccop.bsky.social
Reposted by Michael Fisch MD MPH
SWOG 2210 is open for #prostatecancer patients w/ BRCA1 or BRCA2. Fascinating to see BRCA’s role in other cancers. Hoping we see biomarkers unlock clues in RCC soon. #GUonc #oncsky #cansky
May 3, 2025 at 6:20 PM
SWOG 2210 is open for #prostatecancer patients w/ BRCA1 or BRCA2. Fascinating to see BRCA’s role in other cancers. Hoping we see biomarkers unlock clues in RCC soon. #GUonc #oncsky #cansky
Reposted by Michael Fisch MD MPH
So thrilled to be joined by @missmeganel.bsky.social to discuss her amazing essay “Tamales” in our latest @ascocancer.bsky.social #CancerStories podcast! Listen to how patients invite their doctors into their culture and their world. 🎗️♥️🇲🇽 ascopubs.org/do/tamales-cel…
April 17, 2025 at 8:05 PM
So thrilled to be joined by @missmeganel.bsky.social to discuss her amazing essay “Tamales” in our latest @ascocancer.bsky.social #CancerStories podcast! Listen to how patients invite their doctors into their culture and their world. 🎗️♥️🇲🇽 ascopubs.org/do/tamales-cel…
Reposted by Michael Fisch MD MPH
"If palliative care clinicians walk the line between security and vulnerability, then they must expect to misstep sometimes."
This Viewpoint explores why palliative care clinicians may be at increased risk for dismissal.
#MedSky https://ja.ma/42bomND
This Viewpoint explores why palliative care clinicians may be at increased risk for dismissal.
#MedSky https://ja.ma/42bomND
Why Good Palliative Care Clinicians Get Fired
This Viewpoint discusses why palliative care clinicians may be fired despite good job performance.
ja.ma
April 14, 2025 at 7:00 PM
"If palliative care clinicians walk the line between security and vulnerability, then they must expect to misstep sometimes."
This Viewpoint explores why palliative care clinicians may be at increased risk for dismissal.
#MedSky https://ja.ma/42bomND
This Viewpoint explores why palliative care clinicians may be at increased risk for dismissal.
#MedSky https://ja.ma/42bomND
Reposted by Michael Fisch MD MPH
Clinician researchers should just remove the work "trend" from your vocabulary. Seriously! 😜
If what you are indicating by using that word is actually important, you will be able to find another way to describe it. I promise.
If what you are indicating by using that word is actually important, you will be able to find another way to describe it. I promise.
March 21, 2025 at 10:08 AM
Clinician researchers should just remove the work "trend" from your vocabulary. Seriously! 😜
If what you are indicating by using that word is actually important, you will be able to find another way to describe it. I promise.
If what you are indicating by using that word is actually important, you will be able to find another way to describe it. I promise.
Reposted by Michael Fisch MD MPH
A brief plea to call a spade a spade (or more specifically, call a phase 1 a phase 1; a phase 2 a phase 2; a phase 3 a phase 3). www.europeanurology.com/article/S030...
The Importance of Precise Scientific Communication: Nonrandomized Trials Should Not Be Described as Phase 3, and Registrational-intent Trials Should Not Be Described as Phase 2
Standardized nomenclature for clinical trials is required so that the terms phase
1 (first-in-human dose-finding trials), phase 2 (trials to determine the safety and
efficacy of a drug and the value o...
www.europeanurology.com
March 21, 2025 at 5:29 PM
A brief plea to call a spade a spade (or more specifically, call a phase 1 a phase 1; a phase 2 a phase 2; a phase 3 a phase 3). www.europeanurology.com/article/S030...
Reposted by Michael Fisch MD MPH
Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/...
Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice
ascopubs.org
March 13, 2025 at 10:41 PM
Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists | JCO Oncology Practice ascopubs.org/doi/10.1200/...
Reposted by Michael Fisch MD MPH
Resilience and the Fallacy of “One Size Fits All.”
www.nejm.org/doi/abs/10.1...
@nejm.org @harvardmed.bsky.social @danafarber.bsky.social
#PallOnc #GeriOnc #PalliativeCare
www.nejm.org/doi/abs/10.1...
@nejm.org @harvardmed.bsky.social @danafarber.bsky.social
#PallOnc #GeriOnc #PalliativeCare
February 16, 2025 at 8:04 PM
Resilience and the Fallacy of “One Size Fits All.”
www.nejm.org/doi/abs/10.1...
@nejm.org @harvardmed.bsky.social @danafarber.bsky.social
#PallOnc #GeriOnc #PalliativeCare
www.nejm.org/doi/abs/10.1...
@nejm.org @harvardmed.bsky.social @danafarber.bsky.social
#PallOnc #GeriOnc #PalliativeCare
Reposted by Michael Fisch MD MPH
@fumikochino.bsky.social published in @ascocancer.bsky.social this important #pallonc study
#Fintox 💰 is direct costs (e.g., copays) ➕ indirect costs (e.g., lost income)
➡️: ⬆️stress and skipping #cancer meds.
4 step #COST frame work ⬆️🗣️
🔗: ascopubs.org/doi/10.1200/...
#Fintox 💰 is direct costs (e.g., copays) ➕ indirect costs (e.g., lost income)
➡️: ⬆️stress and skipping #cancer meds.
4 step #COST frame work ⬆️🗣️
🔗: ascopubs.org/doi/10.1200/...
February 19, 2025 at 6:13 PM
@fumikochino.bsky.social published in @ascocancer.bsky.social this important #pallonc study
#Fintox 💰 is direct costs (e.g., copays) ➕ indirect costs (e.g., lost income)
➡️: ⬆️stress and skipping #cancer meds.
4 step #COST frame work ⬆️🗣️
🔗: ascopubs.org/doi/10.1200/...
#Fintox 💰 is direct costs (e.g., copays) ➕ indirect costs (e.g., lost income)
➡️: ⬆️stress and skipping #cancer meds.
4 step #COST frame work ⬆️🗣️
🔗: ascopubs.org/doi/10.1200/...
Reposted by Michael Fisch MD MPH
At some point the US will need to consider value when approving drugs (or at least deciding if we are going to pay for them).
February 20, 2025 at 3:52 AM
At some point the US will need to consider value when approving drugs (or at least deciding if we are going to pay for them).
Reposted by Michael Fisch MD MPH
re: cancer label for lo-risk cancer: either a) relabel "but ensure patients understand [need for] monitoring" or b) don't relabel "but ensure patients understand lesions are unlikely to cause problems, so surveillance is appropriate." We know a) works better then b). jamanetwork.com/journals/jam...
Will Renaming Some Cancers as Noncancers Hurt or Help?
This Medical News article discusses the ongoing debate about whether the word cancer should be dropped from the names of indolent tumors of the prostate and breast.
jamanetwork.com
January 17, 2025 at 9:41 PM
re: cancer label for lo-risk cancer: either a) relabel "but ensure patients understand [need for] monitoring" or b) don't relabel "but ensure patients understand lesions are unlikely to cause problems, so surveillance is appropriate." We know a) works better then b). jamanetwork.com/journals/jam...
Reposted by Michael Fisch MD MPH
Reposted by Michael Fisch MD MPH
Cancer affects all in some way. Change is coming after too brief a period of great leadership by Dr. Kimryn Rathmell. Whatever happens it is an honor to express a vision for the field of cancer research & innovation in oncology. Research on causes & cures brings hope for patients.
January 18, 2025 at 1:55 AM
Cancer affects all in some way. Change is coming after too brief a period of great leadership by Dr. Kimryn Rathmell. Whatever happens it is an honor to express a vision for the field of cancer research & innovation in oncology. Research on causes & cures brings hope for patients.
Reposted by Michael Fisch MD MPH
I, too, have been surprised by the rise of "tornado plots" to plot clinical trial AEs at our conferences!
100% agree with ⬆️ this simple data vis change to improve interpretability of AEs.
100% agree with ⬆️ this simple data vis change to improve interpretability of AEs.
I think a tweak to show the bars next to each other, in the same direction rather than in opposite directions would make it far easier to compare diffs between results from groups.
Isn't the version on the R easier to show where diffs in AEs exist?
IMO, we should do this variant instead. (5/8)
Isn't the version on the R easier to show where diffs in AEs exist?
IMO, we should do this variant instead. (5/8)
January 5, 2025 at 4:34 PM
I, too, have been surprised by the rise of "tornado plots" to plot clinical trial AEs at our conferences!
100% agree with ⬆️ this simple data vis change to improve interpretability of AEs.
100% agree with ⬆️ this simple data vis change to improve interpretability of AEs.
Reposted by Michael Fisch MD MPH
#ESMOImmuno24
Proffered paper🔥
Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social
- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal
Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
Proffered paper🔥
Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social
- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal
Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
December 14, 2024 at 12:07 AM
#ESMOImmuno24
Proffered paper🔥
Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social
- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal
Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
Proffered paper🔥
Ph III CM73L: Nivo+cCRT➡️consol Nivo/Ipi v Nivo v cCRT➡️Durva @solangepeters.bsky.social
- no PFS/OS benefit
- g3+TRAE 57%, 54%, 49%
- concerning pneumonitis signal
Concurrent RT+IO - going going gone
@oncoalert.bsky.social #LCSM #Medsky #Oncsky
Reposted by Michael Fisch MD MPH
1/4 @swog.org lung cancer trial, PRAGMATICA, closes early! This randomized trial enrolled 800 volunteers w stage 3-4 lung cancer in 21 months (goal was 700 in 24m). Tested chemo vs ramicirumab/pembrolizumab. Not applicable to every trial, but...
December 14, 2024 at 11:28 AM
1/4 @swog.org lung cancer trial, PRAGMATICA, closes early! This randomized trial enrolled 800 volunteers w stage 3-4 lung cancer in 21 months (goal was 700 in 24m). Tested chemo vs ramicirumab/pembrolizumab. Not applicable to every trial, but...
Reposted by Michael Fisch MD MPH
Hot of the press from @proteuspros - an infographic explaining the value of PROs!
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
December 13, 2024 at 6:24 PM
Hot of the press from @proteuspros - an infographic explaining the value of PROs!
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
Note - they need to start as parr of the clinical encounter to benefit patients and society.
tinyurl.com/3m594fhk
Reposted by Michael Fisch MD MPH
Remote Symptom Monitoring of Patients With Advanced Lung #Cancer (The ProWide Study): A Randomized Controlled Trial.
ascopubs.org/doi/10.1200/...
@ascopost.bsky.social
#LungCancer #PallOnc #SuppOnc
ascopubs.org/doi/10.1200/...
@ascopost.bsky.social
#LungCancer #PallOnc #SuppOnc
December 13, 2024 at 2:24 AM
Remote Symptom Monitoring of Patients With Advanced Lung #Cancer (The ProWide Study): A Randomized Controlled Trial.
ascopubs.org/doi/10.1200/...
@ascopost.bsky.social
#LungCancer #PallOnc #SuppOnc
ascopubs.org/doi/10.1200/...
@ascopost.bsky.social
#LungCancer #PallOnc #SuppOnc
Reposted by Michael Fisch MD MPH
De-escalation discussion on Europa trial tag line - which would you prefer, 5 days of RT or 5 years of ET…. 🤔🤔 No-brainer?? Supported by BASO II trial longer term data #SABC24
December 12, 2024 at 3:58 PM
De-escalation discussion on Europa trial tag line - which would you prefer, 5 days of RT or 5 years of ET…. 🤔🤔 No-brainer?? Supported by BASO II trial longer term data #SABC24
Reposted by Michael Fisch MD MPH
This is great because patients hate endocrine therapy!
However, we need to see recurrence data before adopting in the clinic.
#BCSM #SABCS24
However, we need to see recurrence data before adopting in the clinic.
#BCSM #SABCS24
📌 EUROPA Trial: Exclusive Endocrine Therapy or Radiation Therapy in Women Aged 70+ Years with Luminal-Like Early Breast Cancer: Preplanned Interim Analysis of a Randomized Phase 3 Trial
@icromeattini.bsky.social 👏🏻👏🏻👏🏻
doi.org/10.1016/S147...
#SABCS24 #GeneralSession2 #Day3 @oncoalert.bsky.social
@icromeattini.bsky.social 👏🏻👏🏻👏🏻
doi.org/10.1016/S147...
#SABCS24 #GeneralSession2 #Day3 @oncoalert.bsky.social
December 12, 2024 at 4:07 PM
Reposted by Michael Fisch MD MPH
#SABCS24 #bcsm #OncSky #RadOnc #MedSky
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
December 12, 2024 at 4:23 PM
#SABCS24 #bcsm #OncSky #RadOnc #MedSky
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
BIG 2-04 SUPREMO: postmastectomy #radiation in int risk #breastcancer did not improve 10y overall survival, incl for node + subset. Stat sig but small ⬇️ in chest wall recurrence (2.5% -> 1.1% abs risk, NNT 63 to prevent 1 CW recurrence)
@oncoalert.bsky.social
Reposted by Michael Fisch MD MPH
Omission of Axillary surgery continues to build momentum
Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org
Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial | NEJM
Whether surgical axillary staging as part of breast-conserving therapy can be omitted
without compromising survival has remained unclear. In this prospective, randomized,
noninferiority trial, we i...
www.nejm.org
December 12, 2024 at 4:54 PM
Omission of Axillary surgery continues to build momentum
Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org
Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org
Reposted by Michael Fisch MD MPH
Dr. Singh draws nice comparisons between SOUND and INSEMA. #SABCS24 @oncoalert.bsky.social @sabcs.bsky.social
December 12, 2024 at 5:02 PM
Dr. Singh draws nice comparisons between SOUND and INSEMA. #SABCS24 @oncoalert.bsky.social @sabcs.bsky.social